Early detection of prostate cancer relapse by biochemistry and diagnostic imaging

L. Evangelista, F. Zattoni, E. Rossi, Robert Jeffrey Karnes, Val Lowe

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Prostate cancer (PCa) is a common malignancy in men associated with an increase in the incidence rate. Radical prostatectomy (RP) or external beam radiotherapy (EBRT) represents the most employed treatments for the local control of disease. However, 10-50% of patients who experienced a recurrence of disease after primary treatments can benefit from salvage or palliative therapies. To date, prostate specific antigen (PSA) is usually used in clinical practice to monitor the status of disease and to early detect the recurrence of PCa. Nevertheless, PSA cannot discriminate the presence of local vs. distant metastatic disease. Circulating tumor cells are considered as a sign of disease widespread, but their correlation with metastatic PCa and local recurrence of disease is still indeterminate. Digital rectal exploration and transrectal ultrasonography are considered the first clinical and diagnostic approach to identify the local recurrence of PCa, but are associated with a low detection rate and low diagnostic accuracies. Conversely, magnetic resonance imaging (MRI) has gained a great importance in this setting of disease, being able to determine the presence of local recurrence with high sensitivity, also in the presence of low serum PSA levels. Lastly, the introduction of positron emission tomography/computed tomography (PET/CT) with radiolabeled choline agents let to improve the management of patients with early recurrence of disease, although its accuracy is linked to the PSA and PSA dynamic values. New radiopharmaceutical agents, like 68Ga-PSMA or 18F-FACBC and others could improve the diagnostic accuracy of PET/CT, but the data is still preliminary. In the present review we will discuss both clinical and diagnostic instrumentations, actually available in clinical practice, able to early identify the presence of recurrent PCa and to differentiate between local and distant relapse of tumor.

Original languageEnglish (US)
Pages (from-to)359-373
Number of pages15
JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
Volume59
Issue number4
StatePublished - Dec 1 2015

Fingerprint

Diagnostic Imaging
Early Detection of Cancer
Biochemistry
Prostatic Neoplasms
Prostate-Specific Antigen
Recurrence
Circulating Neoplastic Cells
Salvage Therapy
Radiopharmaceuticals
Prostatectomy
Choline
Palliative Care
Ultrasonography
Neoplasms
Radiotherapy
Magnetic Resonance Imaging
Incidence
Therapeutics
Serum

Keywords

  • Circulating
  • Magnetic resonance imaging
  • Neoplastic cells
  • Positron-emission tomography
  • Prostate-specific antigen
  • Prostatic neoplasms
  • Tomography
  • Ultrasonography
  • X-ray computed

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Early detection of prostate cancer relapse by biochemistry and diagnostic imaging. / Evangelista, L.; Zattoni, F.; Rossi, E.; Karnes, Robert Jeffrey; Lowe, Val.

In: Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 59, No. 4, 01.12.2015, p. 359-373.

Research output: Contribution to journalArticle

@article{fd8ac15ea4a046ab8715c09a540f45dd,
title = "Early detection of prostate cancer relapse by biochemistry and diagnostic imaging",
abstract = "Prostate cancer (PCa) is a common malignancy in men associated with an increase in the incidence rate. Radical prostatectomy (RP) or external beam radiotherapy (EBRT) represents the most employed treatments for the local control of disease. However, 10-50{\%} of patients who experienced a recurrence of disease after primary treatments can benefit from salvage or palliative therapies. To date, prostate specific antigen (PSA) is usually used in clinical practice to monitor the status of disease and to early detect the recurrence of PCa. Nevertheless, PSA cannot discriminate the presence of local vs. distant metastatic disease. Circulating tumor cells are considered as a sign of disease widespread, but their correlation with metastatic PCa and local recurrence of disease is still indeterminate. Digital rectal exploration and transrectal ultrasonography are considered the first clinical and diagnostic approach to identify the local recurrence of PCa, but are associated with a low detection rate and low diagnostic accuracies. Conversely, magnetic resonance imaging (MRI) has gained a great importance in this setting of disease, being able to determine the presence of local recurrence with high sensitivity, also in the presence of low serum PSA levels. Lastly, the introduction of positron emission tomography/computed tomography (PET/CT) with radiolabeled choline agents let to improve the management of patients with early recurrence of disease, although its accuracy is linked to the PSA and PSA dynamic values. New radiopharmaceutical agents, like 68Ga-PSMA or 18F-FACBC and others could improve the diagnostic accuracy of PET/CT, but the data is still preliminary. In the present review we will discuss both clinical and diagnostic instrumentations, actually available in clinical practice, able to early identify the presence of recurrent PCa and to differentiate between local and distant relapse of tumor.",
keywords = "Circulating, Magnetic resonance imaging, Neoplastic cells, Positron-emission tomography, Prostate-specific antigen, Prostatic neoplasms, Tomography, Ultrasonography, X-ray computed",
author = "L. Evangelista and F. Zattoni and E. Rossi and Karnes, {Robert Jeffrey} and Val Lowe",
year = "2015",
month = "12",
day = "1",
language = "English (US)",
volume = "59",
pages = "359--373",
journal = "Quarterly Journal of Nuclear Medicine and Molecular Imaging",
issn = "1824-4785",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Early detection of prostate cancer relapse by biochemistry and diagnostic imaging

AU - Evangelista, L.

AU - Zattoni, F.

AU - Rossi, E.

AU - Karnes, Robert Jeffrey

AU - Lowe, Val

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Prostate cancer (PCa) is a common malignancy in men associated with an increase in the incidence rate. Radical prostatectomy (RP) or external beam radiotherapy (EBRT) represents the most employed treatments for the local control of disease. However, 10-50% of patients who experienced a recurrence of disease after primary treatments can benefit from salvage or palliative therapies. To date, prostate specific antigen (PSA) is usually used in clinical practice to monitor the status of disease and to early detect the recurrence of PCa. Nevertheless, PSA cannot discriminate the presence of local vs. distant metastatic disease. Circulating tumor cells are considered as a sign of disease widespread, but their correlation with metastatic PCa and local recurrence of disease is still indeterminate. Digital rectal exploration and transrectal ultrasonography are considered the first clinical and diagnostic approach to identify the local recurrence of PCa, but are associated with a low detection rate and low diagnostic accuracies. Conversely, magnetic resonance imaging (MRI) has gained a great importance in this setting of disease, being able to determine the presence of local recurrence with high sensitivity, also in the presence of low serum PSA levels. Lastly, the introduction of positron emission tomography/computed tomography (PET/CT) with radiolabeled choline agents let to improve the management of patients with early recurrence of disease, although its accuracy is linked to the PSA and PSA dynamic values. New radiopharmaceutical agents, like 68Ga-PSMA or 18F-FACBC and others could improve the diagnostic accuracy of PET/CT, but the data is still preliminary. In the present review we will discuss both clinical and diagnostic instrumentations, actually available in clinical practice, able to early identify the presence of recurrent PCa and to differentiate between local and distant relapse of tumor.

AB - Prostate cancer (PCa) is a common malignancy in men associated with an increase in the incidence rate. Radical prostatectomy (RP) or external beam radiotherapy (EBRT) represents the most employed treatments for the local control of disease. However, 10-50% of patients who experienced a recurrence of disease after primary treatments can benefit from salvage or palliative therapies. To date, prostate specific antigen (PSA) is usually used in clinical practice to monitor the status of disease and to early detect the recurrence of PCa. Nevertheless, PSA cannot discriminate the presence of local vs. distant metastatic disease. Circulating tumor cells are considered as a sign of disease widespread, but their correlation with metastatic PCa and local recurrence of disease is still indeterminate. Digital rectal exploration and transrectal ultrasonography are considered the first clinical and diagnostic approach to identify the local recurrence of PCa, but are associated with a low detection rate and low diagnostic accuracies. Conversely, magnetic resonance imaging (MRI) has gained a great importance in this setting of disease, being able to determine the presence of local recurrence with high sensitivity, also in the presence of low serum PSA levels. Lastly, the introduction of positron emission tomography/computed tomography (PET/CT) with radiolabeled choline agents let to improve the management of patients with early recurrence of disease, although its accuracy is linked to the PSA and PSA dynamic values. New radiopharmaceutical agents, like 68Ga-PSMA or 18F-FACBC and others could improve the diagnostic accuracy of PET/CT, but the data is still preliminary. In the present review we will discuss both clinical and diagnostic instrumentations, actually available in clinical practice, able to early identify the presence of recurrent PCa and to differentiate between local and distant relapse of tumor.

KW - Circulating

KW - Magnetic resonance imaging

KW - Neoplastic cells

KW - Positron-emission tomography

KW - Prostate-specific antigen

KW - Prostatic neoplasms

KW - Tomography

KW - Ultrasonography

KW - X-ray computed

UR - http://www.scopus.com/inward/record.url?scp=84945131939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945131939&partnerID=8YFLogxK

M3 - Article

C2 - 26213139

AN - SCOPUS:84945131939

VL - 59

SP - 359

EP - 373

JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging

JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging

SN - 1824-4785

IS - 4

ER -